Systemic immunoglobulin light chain (AL) amyloidosis is a heterogeneous rare disease
driven by a destructive monoclonal gammopathy and typified by misfolded immunoglobulin …

Purpose Autologous hematopoietic cell transplantation, or autotransplantation, is effective in
light-chain amyloidosis (AL), but it is associated with a high risk of early mortality (EM). In a …

Abstract Abstract 3109 Background: High dose melphalan (MEL) is a standard treatment for
eligible patients with AL, a disease in which hematologic response is a key determinant of …

The immunoglobulin light-chain amyloidosis is a multisystemic disease which manifests by
damage to the vital organs by light chain-derived amyloid fibril. Traditionally, the treatment …

Light chain (AL) amyloidosis is the most frequently diagnosed form of systemic amyloid in
the western world. The historically poor prognosis of AL amyloidosis appears to be …

Objectives: The purpose of this study was to address the overall trends in mortality since the
adoption of modern therapies for treatment of systemic amyloidosis, and to reconsider the …

The cardiac involvement and associated mortality that occur in systemic AL amyloidosis
remain among the most challenging aspects of the systemic amyloid-related diseases …

Light chain (AL) amyloidosis is caused by a usually small plasma cell clone producing a
misfolded light chain that deposits in tissues. Survival is mostly determined by the severity of …

Abstract 1364 In light chain (AL) amyloidosis, as well as in multiple myeloma, response to
treatment is increasingly being used as a surrogate endpoint in clinical trials. In 2005 a …

Purpose Autologous stem-cell transplantation (ASCT) has been used in patients with
immunoglobulin light chain (AL) amyloidosis for more than two decades. Early experience …